Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:43:13.751Z.
Calculation as of: 2026-10-06T19:43:13.751Z.
Quote observation: 2026-10-06T19:40:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8b72fc44080d8c671fb5883057af471201fb64a542d8aebba0fac2689ec384f4
PEG RATIO
N/A
Sunshine Biopharma, Inc.
Market Cap
$879977.00
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Sunshine Biopharma, Inc. (SBFM) | $879977.00 | N/A |
| Bone Biologics Corporation (BBLG)vs › | $850879.00 | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $894080.00 | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $835190.00 | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $827771.00 | N/A |
| Ridgetech, Inc. (RDGT)vs › | $814420.00 | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $726206.00 | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A |
| CDT Equity Inc. (CDT)vs › | $695428.00 | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.09M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
